文献速递膀胱癌与上尿路尿路上皮癌

尿路上皮癌组织学亚型的临床结局、基因组异质性与治疗考量

Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma.
PubMed 文献 · Eur Urol · 2025-04-26

该研究纳入3052例根治性膀胱切除术患者分析手术结局,并对1060例膀胱肿瘤进行靶向外显子测序。结果显示浆细胞样、微乳头状、肉瘤样或混合组织学肿瘤的癌症特异性生存差于纯尿路上皮组织学,各亚型具有不同的基因组改变模式和肿瘤突变负荷。

要点

  • 浆细胞样、微乳头状、肉瘤样或混合组织学患者的癌症特异性生存差于纯尿路上皮组织学。
  • ERBB2、FGFR3和PTEN改变分别最常见于微乳头状、巢状/鳞状和肉瘤样尿路上皮癌。
  • 浆细胞样、神经内分泌和微乳头状肿瘤的肿瘤突变负荷最高。

核心结论

  • 伴有异常组织学的尿路上皮癌具有独特的基因组改变模式,可能通过新疗法靶向并影响临床试验纳入。
  • 对于与较差临床结局相关的组织学亚型患者,应探索生物标志物驱动的系统治疗。

研究设计与样本

  • 临床队列包括3052例接受根治性膀胱切除术(伴或不伴新辅助化疗)的患者。
  • 基因组队列对1060例来自根治性膀胱切除术或经尿道切除术标本的膀胱肿瘤进行靶向外显子测序。

主要发现

  • 浆细胞样、微乳头状、肉瘤样或混合组织学肿瘤患者的癌症特异性生存差于纯尿路上皮组织学患者。
  • ERBB2、FGFR3和PTEN改变分别最常见于微乳头状、巢状/鳞状和肉瘤样尿路上皮癌。
  • 肿瘤突变负荷在浆细胞样、神经内分泌和微乳头状肿瘤中最高。
  • 混合组织学肿瘤的形态学不同区域具有共享的克隆起源,但存在例外。

临床怎么用

  • 对伴有异常组织学的尿路上皮癌患者,可考虑基于生物标志物驱动的系统治疗探索。
  • 组织学亚型可能影响临床试验纳入决策。

局限性

  • 研究为回顾性设计,存在选择偏倚的潜在可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Divergent differentiation and histologic subtypes are common findings in urothelial carcinoma (UC). Clinically relevant genomic alterations and oncogenic drivers of individual subtypes remain poorly defined. We characterized surgical outcomes and the genomic landscape of UC with aberrant histology (UCAH), with a focus on biomarkers and targetable alterations. METHODS: The clinical cohort comprised 3052 patients who underwent radical cystectomy (RC) with or without neoadjuvant chemotherapy. Targeted exon sequencing was performed for a genomic cohort of 1060 bladder tumors from RC or transurethral resection specimens. We characterized the frequency of oncogenic mutations and targetable alterations, and the tumor mutational burden (TMB) of each subtype. We defined the clonal relatedness of morphologically distinct regions of tumors with mixed histology. KEY FINDINGS AND LIMITATIONS: Patients with plasmacytoid, micropapillary, sarcomatoid, or mixed-histology tumors had worse cancer-specific survival than patients with pure urothelial histology. ERBB2, FGFR3, and PTEN alterations were most frequent in micropapillary, nested/squamous, and sarcomatoid UC, respectively. TMB was highest in plasmacytoid, neuroendocrine, and micropapillary tumors. Regions of mixed histology had shared clonal origins, but exceptions were observed. The retrospective design and potential for selection bias are limitations of our study. CONCLUSIONS AND CLINICAL IMPLICATIONS: UCAH tumors have distinct patterns of genomic alterations, which may be targetable via novel therapies and have implications for clinical trial inclusion. Biomarker-driven systemic therapy should be explored in patients with histologic subtypes that are associated with worse clinical outcomes.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Chu CE, Chen Z, Whiting K, et al. Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma. Eur Urol. 2025. PMID: 40288936. doi:10.1016/j.eururo.2025.04.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。